iShares China Large-Cap ETF vs Indivior Pharmaceuticals Inc. Common Stock — how do they compare? iShares China Large-Cap ETF trades at $33.83 (market cap $3.93B), while Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B). The key difference: iShares China Large-Cap ETF and Indivior Pharmaceuticals Inc. Common Stock are close in size by market cap, and Indivior Pharmaceuticals Inc. Common Stock is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and Indivior Pharmaceuticals Inc. Common Stock for 0 Days on average.
| FXI | INDV | |
|---|---|---|
Market Cap | $3.93B | $4.18B |
Volume | 14,707,409 | 1,819,746 |
52-Week High | $41.08 | $41.83 |
52-Week Low | $31.59 | $24.09 |
Typical Hold Time | 151 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $4.47B |
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $34.17 with minimal daily movement (+0.09%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. Recent news highlights China's mixed economic signals, including strong corporate profit growth but concerns over industrial overcapacity and trade tensions. The ETF offers value exposure with a P/E ratio approximately half that of the S&P 500, but faces significant geopolitical and economic headwinds.
The outlook for FXI remains clouded by US-China relations and domestic economic challenges. Investment opportunity lies in its valuation discount versus US equities and potential policy support from Chinese authorities. Key risks include escalating trade protectionism, weak domestic consumption, and regulatory uncertainty. Analyst sentiment is divided, reflecting the high-risk, high-reward nature of Chinese large-cap exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →